<DOC>
	<DOCNO>NCT02491983</DOCNO>
	<brief_summary>This international , randomize , open-label , control , multicenter phase II clinical trial investigate compare safety efficacy palbociclib combine fulvestrant letrozole woman ER+ , HER2- locally advance metastatic breast cancer .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Palbociclib Combination With Fulvestrant Letrozole Patients With ER+ , HER2- Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Women 18 year older metastatic locally advanced disease , amenable curative therapy Confirmed diagnosis HR+/HER2 breast cancer Postmenopausal status No prior chemotherapy line metastatic setting Measurable disease define RECIST version 1.1 , nonmeasurable disease Eastern Cooperative Oncology Group ( ECOG ) PS 01 Adequate organ marrow function , resolution toxic effect prior therapy surgical procedure Confirmed diagnosis HER2 positive disease Patients rapidly progressive visceral disease visceral crisis . Locally advanced breast cancer candidate radical treatment . Prior ( neo ) adjuvant endocrine treatment DFI â‰¤ 12months completion treatment . Major surgery within 4 week start study drug Serious concomitant systemic disorder incompatible study Known active uncontrolled symptomatic CNS metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>Endocrine receptor positive</keyword>
	<keyword>HER-2 negative</keyword>
</DOC>